Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
Sign Up to like & getrecommendations! Published in 2018 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2018.1464203
Abstract: Abstract Objectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim to assess the efficacy and safety of switching from originator infliximab… read more here.
Keywords: response; originator; efficacy; infliximab originator ... See more keywords
FRI0329 Efficacy and safety of infliximab originator in patients with takayasu arteritis within the RTU (temporary recommendation of use) in france
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1793
Abstract: Background The benefit/risk ratio of infliximab in refractory patient with Takayasu arteritis (TA) is assumed to be favorable, based on retrospective studies with limited sample size [1, 2] in which infliximab has been prescribed off-label.… read more here.
Keywords: originator; infliximab originator; efficacy; takayasu arteritis ... See more keywords